Clinical Trial Update: A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CP-690,550 (tofacitinib) for safety and efficacy in moderate-to-severe ulcerative colitis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED | Results posted: 2013-04-16